Fractyl Health, Inc. (NASDAQ:GUTS) Short Interest Update

Key Points

• Fractyl Health, Inc. saw a significant increase in short interest, rising by 175.7% in September, totaling 4,660,000 shares as of September 30th.
• Analysts have provided mixed ratings, with a consensus rating of "Moderate Buy" and a price target of $6.90, while HC Wainwright recently lowered its target price from $9.00 to $8.00.
• The company reported (-$0.53) earnings per share for the last quarter, missing estimates, and is predicted to post -1.61 EPS for the current fiscal year.

Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) was the target of a large growth in short interest in September. As of September 30th, there was short interest totaling 4,660,000 shares, a growth of 175.7% from the September 15th total of 1,690,000 shares. Approximately 4.5% of the shares of the stock are short sold. Based on an average daily volume of 2,810,000 shares, the short-interest ratio is currently 1.7 days. Based on an average daily volume of 2,810,000 shares, the short-interest ratio is currently 1.7 days. Approximately 4.5% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. LADENBURG THALM/SH SH assumed coverage on Fractyl Health in a report on Thursday, August 28th. They set a "buy" rating and a $3.60 price objective on the stock. HC Wainwright decreased their target price on Fractyl Health from $9.00 to $8.00 and set a "buy" rating on the stock in a research note on Friday, September 26th. Weiss Ratings restated a "sell (e+)" rating on shares of Fractyl Health in a research note on Wednesday, October 8th. Finally, Canaccord Genuity Group decreased their target price on Fractyl Health from $12.00 to $6.00 and set a "buy" rating on the stock in a research note on Thursday, August 14th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $6.90.

Fractyl Health Price Performance

GUTS opened at $1.29 on Friday. The stock has a 50-day moving average price of $1.12 and a 200-day moving average price of $1.45. Fractyl Health has a 12-month low of $0.83 and a 12-month high of $3.48. The company has a current ratio of 1.22, a quick ratio of 1.22 and a debt-to-equity ratio of 4.61. The stock has a market capitalization of $64.87 million, a P/E ratio of -0.63 and a beta of 2.27.

Fractyl Health (NASDAQ:GUTS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.16). Equities analysts predict that Fractyl Health will post -1.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Fractyl Health

Hedge funds and other institutional investors have recently modified their holdings of the company. Catalyst Funds Management Pty Ltd purchased a new position in shares of Fractyl Health in the 2nd quarter worth about $26,000. Jane Street Group LLC purchased a new position in shares of Fractyl Health in the 2nd quarter worth about $31,000. Chicago Partners Investment Group LLC purchased a new position in shares of Fractyl Health in the 1st quarter worth about $37,000. HighTower Advisors LLC boosted its holdings in shares of Fractyl Health by 57.9% in the 1st quarter. HighTower Advisors LLC now owns 40,921 shares of the company's stock worth $49,000 after purchasing an additional 15,000 shares in the last quarter. Finally, Osaic Holdings Inc. boosted its holdings in shares of Fractyl Health by 460.3% in the 2nd quarter. Osaic Holdings Inc. now owns 59,645 shares of the company's stock worth $97,000 after purchasing an additional 49,000 shares in the last quarter.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.